Non-small cell lung cancer+1
Not recruitingStudy Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer
Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer
- Disease:Non-small cell lung cancerNon-small cell lung cancer stage IIIB
- Substances:CrizotinibRepotrectinib
Hungary- Participants:18–64 years · 65+ years
- Substances:Crizotinib
- Sponsor:Bristol-Myers Squibb Services Unlimited Company

















